We have established a broad Kidney Health Alliance with Vifor Pharma, a world leader in delivering quality care for patients with kidney disease. With establish license agreements to commercialize avacopan and CCX140 in certain licensed territories outside the U.S., we believe that Vifor Pharma will be a valuable resource for the development and potential commercialization of these product candidates. In aggregate, the Vifor Pharma agreements provide $155 million in upfront cash commitments, $1.2 billion in potential development, regulatory and sales milestone payments and royalties in the teens to mid-twenties on net sales in the Vifor Pharma territories.
Additionally, the agreements provide the following:
- Avacopan: ChemoCentryx retains all rights for avacopan (CCX168) for orphan and renal diseases in the U.S. and China and control for worldwide development of avacopan. Vifor Pharma has rights to commercialize avacopan in the rest of the world.
- CCX140: ChemoCentryx retains development control and commercial rights for CCX140 for rare renal diseases including FSGS in the U.S. and China. Vifor Pharma has commercialization rights in the rest of the world. Vifor Pharma also has a future option to solely develop and commercialize CCX140 in chronic kidney disease (CKD) while ChemoCentryx would retain co-promotion rights in the U.S. in CKD.
Vifor Pharma, together with its nephrology partner company Vifor Fresenius Medical Care Renal Pharma, is a world leader in delivering quality care for patients with kidney disease. Vifor Pharma’s renal medicines specialization, including access to a vast patient database and nephrology-focused commercial expertise, will be a valuable resource for the development and potential commercialization of avacopan and CCX140. We believe that the establishment of this Kidney Health Alliance with Vifor Pharma further validates the ChemoCentryx approach to blocking chemoattractant receptors such as C5aR and CCR2 in the inflammatory processes in several rare renal diseases.